Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.46 |
| ▸ | DRD3 | P35462 | 10/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198557 | 0.86 | DRD2 (0.59) | DRD2DRD3KCNH2S1PR1HDAC1 | |
| SCHEMBL2199747 | 0.84 | HDAC1 (0.49) | DRD2DRD3KCNH2HDAC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL2199631 | 0.81 | DRD2 (0.51) | DRD2DRD3KCNH2S1PR1HDAC1 | |
| SCHEMBL31662444 | 0.77 | RAB9A (0.47) | DRD2DRD3KCNH2S1PR1HDAC1 | |
| SCHEMBL31662551 | 0.77 | DRD2 (0.48) | DRD2DRD3KCNH2S1PR1HDAC1 | |
| SCHEMBL3712107 | 0.76 | S1PR1 (0.48) | DRD2DRD3KCNH2S1PR1HDAC1 | |
| SCHEMBL10498818 | 0.74 | S1PR1 (0.52) | DRD2DRD3S1PR1HDAC1CYP1A1 | |
| SCHEMBL10498451 | 0.72 | KDM4E (0.49) | DRD2DRD3S1PR1HDAC1RAB9A | |
| SCHEMBL4921733 | 0.72 | CRBN (0.41) | DRD2DRD3KCNH2 | |
| SCHEMBL8558181 | 0.72 | S1PR1 (0.50) | DRD2DRD3KCNH2S1PR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | TRIESELMANN THOMAS | 2008-09-25 | — | — | US | disclosed |
| CN-101094837-A | Novel beta agonists, method for producing the same and their use as drugs | BOEHRINGER INGELHEIM INT (DE) | 2007-12-26 | — | — | CN | disclosed |
| EP-1781620-A1 | NOVEL BETA AGONISTS, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2005108373-A1 | NOVEL BETA AGONISTS, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | WO | disclosed |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | DRD2 704/4885DRD3 586/4885KCNH2 990/4885 |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | DRD2 704/4885DRD3 586/4885KCNH2 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.